- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|CBP30 targets the CBP/p300 bromodomain, with much improved selectivity compared to the pan-BET bromodomain inhibitor (+)-JQ1 . CBP30 has therapeutic potential against autoimmune diseases characterised by aberrant Th17 responses.
This is a compound from the Structural Genomics Consortium's (SGC) Epigenetics Probes Collection.
|GtoPdb PubChem SID||187051830|
|RCSB PDB Ligand||2LO|
|Search Google for chemical match using the InChIKey||GEPYBHCJBORHCE-SFHVURJKSA-N|
|Search Google for chemicals with the same backbone||GEPYBHCJBORHCE|
|Search UniChem for chemical match using the InChIKey||GEPYBHCJBORHCE-SFHVURJKSA-N|
|Search UniChem for chemicals with the same backbone||GEPYBHCJBORHCE|
79941 (in complex with CREB binding protein)
79942 (in complex with E1A binding protein p300)
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 4889